Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of serum microRNAs associated with prostate cancer in a mouse model of disease

ABSTRACT: There is an urgent need for new biomarkers to enhance the clinical management of prostate cancer. Circulating microRNAs (miRNAs) are emerging as useful non-invasive markers of disease. The objective of this study was to test the utility of a mouse model of prostate cancer as a tool to discover serum miRNAs that could be applied in a clinical setting. Global miRNA profiling using microarrays identified 46 miRNAs at differential levels in the serum of TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice compared to their wild-type littermates.

ORGANISM(S): synthetic construct Mus musculus

PROVIDER: GSE29314 | GEO | 2011/05/20

SECONDARY ACCESSION(S): PRJNA138651

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification of serum microRNAs associated with prostate cancer in a mouse model of disease

Project description:There is an urgent need for new biomarkers to enhance the clinical management of prostate cancer. Circulating microRNAs (miRNAs) are emerging as useful non-invasive markers of disease. The objective of this study was to test the utility of a mouse model of prostate cancer as a tool to discover serum miRNAs that could be applied in a clinical setting. Global miRNA profiling using microarrays identified 46 miRNAs at differential levels in the serum of TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice compared to their wild-type littermates. Total RNA extracted from the serum of 9 mice with advanced disease was pooled into 3 groups (TRAMP serum RNA 1, 2 and 3). Serum RNA from age-matched wild-type littermates, pooled as above, served as the control set.

2011-05-20 | E-GEOD-29314 | biostudies-arrayexpress

The Correlation among Serum Proteomics and Clinical Profiles in Fibromyalgia Women

Project description:Fibromyalgia (FM) is a multifactorial disorder with unclear pathomechanism. There’s an urgent need to explore the potential biomarkers and correlate with the clinical profiles in FM to facilitate the specific management of FM patients. This study aims to 1) investigate the differential serum proteome profiles in patients with FM and healthy controls and 2) explore the correlation between serum proteome and clinical profiles in FM patients

2020-05-17 | PXD013905 | JPOST Repository

Detection of Aggressive Prostate Cancer-Associated Glycoproteins in Urine using Glycoproteomics and Mass Spectrometry

Project description:Clinical management of prostate cancer remains a significant challenge due to the lack of available tests for guiding treatment decisions. The blood Prostate-Specific Antigen (PSA) test has facilitated early detection and intervention of prostate cancer. However, blood PSA levels are less effective in distinguishing aggressive from indolent prostate cancers and other benign prostatic diseases. Thus, the development of novel approaches specific for prostate cancer that can differentiate aggressive from indolent disease remains an urgent medical need. In the current study, we evaluated urine specimens from prostate cancer patients instead of serum using liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the aim of identifying effective prostate cancer biomarkers. Glycoproteins from urine samples of prostate cancer patients with different Gleason scores were characterized via solid phase extraction of N-linked glycosite-containing peptides and LC-MS/MS. In total, 2923 unique glycosite-containing peptides were identified. Comparison of urine-based glycoproteins with those identified from aggressive and non-aggressive prostate cancer tissues as well as sera from prostate cancer patients revealed that the majority of aggressive prostate cancer-associated glycoproteins were more readily detected in patient urine than serum samples. Our data collectively indicate that urine provides a highly reliable source for biomarker testing in patients with aggressive prostate cancer.

2022-02-28 | PXD004495 | Pride

Different miRNA expression profiles between human breast cancer turmors and serum

2014-04-10 | GSE56614 | GEO

Real-time quantitative PCR analysis of pre-treatment serum microRNAs from patients with prostate cancer

Project description:The overall goal of the study was to determine if serum or serum EV microRNAs added prognostic value to current clinical nomograms for prostate cancer. Serum was collected from 203 patients with biopsy-proven prostate cancer. EVs were isolated from the 132 serum samples. RNA was isolated from these serum and serum EV samples, and 61 microRNAs were quantified per sample on a custom qPCR plate. The microRNA data was normalized using NormFinder. The normalized microRNA data was then compared to adverse pathology and prostate biopsy Gleason grade group.

2023-09-22 | GSE228371 | GEO

Exosomal miRNAs from serum sequencing

Project description:Exosomal miRNAs from serum sequencing

| PRJNA1100526 | ENA

Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation

Project description:Accurate assessment of treatment response and residual disease is indispensable for the evaluation of cancer treatment efficacy. However, performing tissue biopsies for longitudinal follow-up poses a major challenge in the management of solid tumours like neuroblastoma. In the present study, we evaluated whether circulating miRNAs are suitable to monitor neuroblastoma tumour burden and whether treatment-induced changes of miRNA abundance in the tumour are detectable in serum. We performed small RNA sequencing on longitudinally collected serum samples from mice carrying orthotopic neuroblastoma xenografts that were exposed to treatment with idasanutlin or temsirolimus. We identified 57 serum miRNAs to be differentially expressed upon xenograft tumour manifestation, out of which 21 were also found specifically expressed in the serum of human high-risk neuroblastoma patients. The murine serum levels of these 57 miRNAs correlated with tumour tissue expression and tumour volume, suggesting potential utility for monitoring tumour burden. In addition, we describe serum miRNAs that dynamically respond to p53 activation following treatment of engrafted mice with idasanutlin. We identified idasanutlin-induced serum miRNA expression changes upon one day and 11 days of treatment. By limiting to miRNAs with a tumour-related induction, we put forward hsa-miR-34a-5p as a potential pharmacodynamic biomarker of p53 activation in serum.

| EGAS00001006678 | EGA

Expression of exosomal microRNAs in bovine serum with clinical or subclinical mastitis

Project description:Bovine mastitis causes changes in the serum exosomal miRNAs expression. Serum samples from healthy dairy cows (n = 7) were compared to those of cows with subclinical (n = 7 ) using small RAN sequencing. Three hundred fifty-five miRNAs (341 known and 14 novel ones) were identified. There were 42 miRNAs up-regulated in serum-derived EVs from cows with subclinical mastitis, including bta-miR-1246, bta-miR-2431-3p, bta-miR-126-3p, bta-miR-29a, etc. The MAPK signaling pathway was the most affected pathway by clinical mastitis. Thus, miRNA alterations in mastitis serum-derived EVs support the potential regulator role of specific miRNAs as exosomal cargo in clinical mastitis physiology.

2022-08-31 | GSE202849 | GEO

Different miRNA expression profiles between human breast cancer turmors and serum

Project description:We identified total 174 significantly differentially expressed miRNAs between tumors and the normal tissues, and 109 miRNAs between serum from patients and serum from healthy individuals. There are only 10 common miRNAs. This suggests that only a small portion of tumor miRNAs are released into serum selectively. Interestingly, the expression change pattern of 28 miRNAs is opposite between breast cancer tumors and serum. Functional analysis shows that the differentially expressed miRNAs and their target genes form a complex interaction network affecting many biological processes and involving in cancer-related pathways such as prostate, basal cell carcinoma, acute myeloid leukymia, and more. A bunch of miRNAs have been demonstrated to be aberrantly expressed in cancer tumor tissue and serum. The miRNA signatures identified from the serum samples could serve as potential noninvasive diagnostic markers for breast cancer. The roles of the miRNAs in cancerigenesis is unclear. In this study, we generated the expression profiles of miRNAs from the paired breast cancer tumors, normal, tissue, and serum samples from eight patients using small RNA-sequencing. Serum samples from eight healthy individuals were used as normal controls.

2014-04-10 | E-GEOD-56614 | biostudies-arrayexpress

Gene expression profile of Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP)

Project description:Gene expression profile of Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) reveals murine targets for preclinical development of human prostate cancer therapy In this study, we have generated an open source TRAMP microarray dataset to identify differentially expressed genes from human prostate cancer that have concordant expression in TRAMP tumors, and thereby represent lead targets for preclinical therapy development. Affymetrix Mouse 430 2.0 chips were used for microarrays of total RNA from 9 TRAMP tumors and 9 normal prostates (ventral and dorsolateral lobes). Keywords: prostate cancer, TRAMP

2008-12-31 | GSE10525 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data